Table 1.
This table describes hedgehog inhibitors which are FDA approved or undergoing clinical trials for various cancers.
| Compound | Target molecule | Stage | Cancer | Reference |
|---|---|---|---|---|
| GDC-0449 vismodegib |
SMO | FDA approved | Basal cell carcinoma | [124] |
| GDC-0449 vismodegib |
SMO | Undergoing clinical trials | Pancreatic cancer Colorectal cancer Prostate cancer Breast cancer |
[125], [126] |
| Glasdegib | SMO | FDA approved | Acute myeloid leukemia | [127] |
| LDE225 Sonidegib |
SMO | FDA approved | Basal cell carcinoma | [128] |
| IPI-926 Saridegib |
SMO | Undergoing clinical trials | chondrosarcoma | [126] |
| Taladegib | SMO | Advanced solid tumors Esophageal cancer Colon cancer |
[129] | |
| BMS-833923 | SMO | Undergoing clinical trials | Advanced or metastatic gastric, gastroesophageal, or esophageal adenocarcinomas |
[125], [126] |
| Itraconazole | SMO | Undergoing clinical trials | Basal cell carcinoma Prostate cancer Non-small cell lung cancer |
[130] |
| Vitamin D | SMO | Undergoing clinical trials | Basal cell carcinoma Acute myeloid leukemia |
[126] |
| Arsenic trioxide | GLI | Undergoing clinical trials | Advanced Basal cell carcinoma Acute myeloid leukemia |
[131] |